How did a twice daily metered dose inhaler, of budesonide-glycopyrrolate-formoterol, compare with a once daily dry powder inhaler, of fluticasone-umeclidinium-vilanterol, in patients with chronic obstructive pulmonary disease? New Research investigates bmj.com/content/387/bm…

🚨 Just out today (online)! 🚨 Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data. With co-authors: Leah Rand, William Feldman, and Aaron Kesselheim from Program On Regulation, Therapeutics, And Law, Brigham and Women’s Research, Harvard Medical School.

Dems can win back some of the public’s trust by building an agenda around game-changing ideas *if* they address systemic issues like patent abuse at their root, rather than continuing to settle for legislation that is watered down and incremental at best.🧵

Bil and Shanon Schmidtknecht are filing a wrongful death and negligence lawsuit, accusing Optum Rx of illegally denying their son his “life-saving” inhaler. wapo.st/3ExPGMD

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved? Read the full Perspective by William B. Feldman, MD, DPhil, MPH (William Feldman),

To my fellow Docs, Nurses and Allied Health Professionals — Rise Up. We need more of us in elected positions. I will have your back, as will many others. This is how change happens. New, sane blood.

Real-world evidence is a vital tool for informing treatment strategies in chronic obstructive pulmonary disease #COPD, write William Feldman and colleagues bmj.com/content/388/bm…

Perspective by William B. Feldman, MD, DPhil, MPH (William Feldman), and Gregg Furie, MD: The Moral Injury of Inhaler Prescribing nej.md/4hO0YLB #MedicalEthics #PublicHealth

"In vertical integration, when PBMs and pharmacies in pairs are all owned by the same company, it can lead to reduced choices at the pharmacy and bad outcomes for patients." William Feldman answers Congressman Chuy García and explains how PBMs are raising costs for consumers.👇